Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
UK
Biotech
British biotech funding‘s ‘signs of recovery,’ but still no IPOs
The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign of recovery.”
James Waldron
Apr 27, 2026 6:59am
AstraZeneca keeps UK research site on pause, but options open
Jan 26, 2026 9:25am
British biotechs mull going public after yearslong IPO drought
Jan 26, 2026 1:01am
Amgen weaves in UK biotech with up to $840M acquisition
Jan 6, 2026 10:35am
Medtronic to double its London center for AI, robotic surgery
Sep 23, 2025 2:30pm
Sanofi becomes latest pharma to hold fire on UK R&D investments
Sep 15, 2025 10:14am
